Contrast-enhanced MR diffusion and perfusion were able to differentiate between central gland prostate cancer and benign prostate hyperplasia, according to a study published in Radiology.
Contrast-enhanced MR diffusion and perfusion were able to differentiate between central gland prostate cancer and benign prostate hyperplasia, according to a study published in Radiology.
The apparent diffusion coefficient differs significantly between central gland carcinoma, stromal hyperplasia, and glandular hyperplasia. Using ADC can help physicians distinguish between cancerous and benign tissue. In addition, combining the rate of contrast transfer between blood and tissue with the ADC can also aid the detection of central gland cancer.
In their retrospective study, the University of Chicago researchers included 49 patients who underwent endorectal MR imaging followed by radical prostatectomy, 26 of whom had central gland cancer.
The researchers found the ADC was 1.05 for central gland carcinoma, 1.27 for stromal hyperplasia foci, and 1.73 for glandular hyperplasia foci. Perfusion parameters were similar in central gland carcinomas and stromal hyperplasia foci. Adding the contrast agent transfer rate between blood and tissue to the ADC increased sensitivity from 38% to 57%. Adding the contrast agent transfer rate between blood and tissue to the ADC increased specificity to 90%.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.